Referanser

1. Polman CH, O’Connor PW, Havrdova E, et al, for the AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New Engl J Med. 2006;354:899–910.
2. TYSABRI® (natalizumab) produktresumé.
3. Data on file, Biogen Idec.
4. French-Constant C. Pathogenesis of multiple sclerosis. Lancet. 1994;343:271–275.
5. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against ?4?1 integrin. Nature. 1992;356:63–66.
6. Baron JL, Madri JA, Ruddle NH, Hashim G, Janway CA Jr. Surface expression of ?4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med. 1993;177:57–68.
7. von Andrian UH, Engelhardt B. ?4 integrins as therapeutic targets in autoimmune disease. N Engl J Med. 2003;348:68–72.
8. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. New Engl J Med. 2006;354:924–933.
9. Biogen Idec Press release 22/7-08, www.biogenidec.com